Autoimmune Disease

Celera Group, a molecular diagnostics business, engages in the identification and validation of diagnostic markers using proprietary genomics and proteomics discovery platforms.

Merrimack Pharmaceuticals are dedicated to the discovery and development of innovative therapies for the treatment of autoimmune disease and cancer. Merrimack is advancing a robust pipeline of clinical and early-stage biologics that represent the next generation of patient-directed, targeted therapies.

Elan Drug Technologies (EDT) is the world’s leading drug delivery company and is a business unit of Elan (NYSE:ELN). The company focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry. Their NanoCrystal® technology is a proven innovation for poorly water-soluble compounds, manufactured to the nanoscale it has five licensed products commercialized to date.